Lisa A. Jackson is an internist and infectious disease epidemiologist who has spent the past 20 years conducting clinical and epidemiologic studies of vaccine safety and efficacy.
In addition to her role as a senior scientific investigator at Group Health Research Institute (GHRI), she is a research professor in the University of Washington (UW) Department of Epidemiology and an adjunct research professor in the UW Department of Medicine
Dr. Jackson is the principal investigator (PI) at Group Health of the Vaccine Safety Datalink Project sponsored by the Centers for Disease Control and Prevention. She is also PI of the Vaccine and Treatment Evaluation Unit hosted by GHRI, one of eight such facilities nationwide that are sponsored by the National Institutes of Health.
Dr. Jackson has authored more than 140 peer-reviewed publications and 14 book chapters. She is a past member of the Food and Drug Administration’s Vaccines and Related Biological Products Advisory Committee and the National Vaccine Advisory Committee.
Dr. Jackson received her medical degree from the University of Virginia School of Medicine, Charlottesville, and her master of public health degree from the University of Washington School of Public Health and Community Medicine.
Vaccine safety; influenza vaccine effectiveness in the elderly; methodologic issues in vaccine effectiveness evaluations; pneumococcal polysaccharide vaccine effectiveness; pneumococcal conjugate vaccine immunogenicity in the elderly; epidemiology of E. coli bacteremia; epidemiology of community-acquired pneumonia
Sukumaran L, McCarthy NL, Li R, Weintraub E, Jacobsen SJ, Hambidge SJ, Jackson LA, Naleway AL, Chan B, Tao B, Gee J. Demographic characteristics of members of the Vaccine Safety Datalink (VSD): a comparison with the United States population. Vaccine. 2015 Jul 22. pii: S0264-410X(15)00984-6. doi: 10.1016/j.vaccine.2015.07.037. [Epub ahead of print]. PubMed
Jackson LA, Campbell JD, Frey SE, Edwards KM, Keitel WA, Kotloff KL, Berry AA, Graham I, Atmar RL, Creech CB, Thomsen IP, Patel SM, Gutierrez AF, Anderson EL, El Sahly HM, Hill H, Noah DL, Bellamy AR. Effect of varying doses of a monovalent H7N9 influenza vaccine with and without AS03 and MF59 adjuvants on immune response: a randomized clinical trial. JAMA. 2015;314(3):237-46. doi: 10.1001/jama.2015.7916. PubMed
Frey SE, Wald A, Edupuganti S, Jackson LA, Stapleton JT, Sahly HE, El-Kamary SS, Edwards K, Keyserling H, Winokur P, Keitel W, Hill H, Goll JB, Chaplin P, Belshe RB; DMID - MVA Study Group, Anderson EL, Graham IL, Johnston C, Mulligan M, Rouphael N, Atmar R, Patel S, Chen W, Kotloff K, Creech CB. Comparison of lyophilized versus liquid modified vaccinia Ankara (MVA) formulations and subcutaneous versus intradermal routes of administration in healthy vaccinia-naïve subjects. Vaccine. 2015 Jul 1. pii: S0264-410X(15)00876-2. doi: 10.1016/j.vaccine.2015.06.075. [Epub ahead of print]. PubMed
Benoit A, Beran J, Devaster JM, Esen M, Launay O, Leroux-Roels G, McElhaney JE, Oostvogels L, van Essen GA, Gaglani M, Jackson LA, Vesikari T, Legrand C, Tibaldi F, Innis BL, Dewe W. Hemagglutination inhibition antibody titers as a correlate of protection against seasonal A/H3N2 influenza disease. Open Forum Infect Dis. 2015 May 14;2(2):ofv067. doi: 10.1093/ofid/ofv067. eCollection 2015. PubMed
Vaccine Treatment and Evaluation Unit tests real-world use to prepare for H7N9.
Read it in News and Events.
The Seattle Times, July 21, 2015